

## Recombinant Rat CD80/B7-1 protein (His Tag)

**Catalog Number:** PDER100212

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

|                      |  |
|----------------------|--|
| <b>Species</b>       | Rat  |
| <b>Source</b>        | E.coli-derived Rat CD80 protein Gly41-Ala262, with an N-terminal His |
| <b>Calculated MW</b> | 24.3 kDa   |
| <b>Observed MW</b>   | 32 kDa   |
| <b>Accession</b>     | G3V671   |
| <b>Bio-activity</b>  | Not validated for activity   |

### Properties

|                       |  |
|-----------------------|--|
| <b>Purity</b>         | > 95% as determined by reducing SDS-PAGE.  |
| <b>Endotoxin</b>      | < 10 EU/mg of the protein as determined by the LAL method  |
| <b>Storage</b>        | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| <b>Shipping</b>       | This product is provided as lyophilized powder which is shipped with ice packs.  |
| <b>Formulation</b>    | Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5% Mannitol.  |
| <b>Reconstitution</b> | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.   |

### Data



> 95 % as determined by reducing SDS-PAGE.

### Background

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

### For Research Use Only

Toll-free: 1-888-852-8623  
Web: [www.elabscience.com](http://www.elabscience.com)

Tel: 1-832-243-6086  
Email: [techsupport@elabscience.com](mailto:techsupport@elabscience.com)

Fax: 1-832-243-6017